KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.verified

KALV

Price:

$11.82

Market Cap:

$498.67M

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, ...[Read more]

Industry

Biotechnology

IPO Date

2015-04-09

Stock Exchange

NASDAQ

Ticker

KALV

The PE Ratio as of June 2024 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is -3.79

According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.79. This represents a change of 19.33% compared to the average of -3.18 of the last 4 quarters.

KalVista Pharmaceuticals, Inc. (KALV) Historical PE Ratio (quarterly & annually)

How has KALV PE Ratio performed in the past?

The mean historical PE Ratio of KalVista Pharmaceuticals, Inc. over the last ten years is -6.33. The current -3.79 PE Ratio has changed 5.89% with respect to the historical average. Over the past ten years (40 quarters), KALV's PE Ratio was at its highest in in the September 2016 quarter at 0. The PE Ratio was at its lowest in in the April 2018 quarter at -39.52.

Quarterly (TTM)
Annual

Average

-6.33

Median

-5.41

Minimum

-16.66

Maximum

-0.53

KalVista Pharmaceuticals, Inc. (KALV) PE Ratio by Quarter and Year

Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 246.92%

Maximum Annual PE Ratio = -0.53

Minimum Annual Increase = -81.32%

Minimum Annual PE Ratio = -16.66

Quarterly (TTM)
Annual
YearPE RatioChange
2023-3.31-27.32%
2022-4.55-57.56%
2021-10.7261.13%
2020-6.65-60.09%
2019-16.66165.23%
2018-6.28246.92%
2017-1.81241.70%
2016-0.53-81.32%
2014-2.84-71.45%
2013-9.94-63.84%

KalVista Pharmaceuticals, Inc. (KALV) Average PE Ratio

How has KALV PE Ratio performed in the past?

The current PE Ratio of KalVista Pharmaceuticals, Inc. (KALV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.19

5-year avg

-8.38

10-year avg

-6.33

KalVista Pharmaceuticals, Inc. (KALV) PE Ratio vs. Peers

How is KALV’s PE Ratio compared to its peers?

KalVista Pharmaceuticals, Inc.’s PE Ratio is greater than Crinetics Pharmaceuticals, Inc. (-13.73), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Kura Oncology, Inc. (-10.33), less than Viridian Therapeutics, Inc. (-3.42), less than Replimune Group, Inc. (-2.22), greater than Nuvectis Pharma, Inc. (-5.07), less than Lyra Therapeutics, Inc. (-0.25), less than Kronos Bio, Inc. (-0.53), less than Gossamer Bio, Inc. (-0.68), greater than Syndax Pharmaceuticals, Inc. (-7.04), greater than Cogent Biosciences, Inc. (-3.93), greater than Cullinan Oncology, Inc. (-6.18), less than Mersana Therapeutics, Inc. (-1.84), greater than Immunocore Holdings plc (-23.08), greater than Mirum Pharmaceuticals, Inc. (-9.92), greater than Larimar Therapeutics, Inc. (-9.49), greater than Cytokinetics, Incorporated (-10.14), greater than DICE Therapeutics, Inc. (-23.17), greater than Edgewise Therapeutics, Inc. (-14.37), greater than Karuna Therapeutics, Inc. (-29.52), greater than Dyne Therapeutics, Inc. (-10.01),

Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is KalVista Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for KalVista Pharmaceuticals, Inc. (KALV)?

What is the highest PE Ratio for KalVista Pharmaceuticals, Inc. (KALV)?

What is the 3-year average PE Ratio for KalVista Pharmaceuticals, Inc. (KALV)?

What is the 5-year average PE Ratio for KalVista Pharmaceuticals, Inc. (KALV)?

How does the current PE Ratio for KalVista Pharmaceuticals, Inc. (KALV) compare to its historical average?